Why the study?
Elevated circulating lactate is a recognized prognostic biomarker in septic cardiomyopathy, but the mechanisms by which it exacerbates cardiac pathology are not fully understood.
Population
Cardiomyocytes in vitro and a murine model of sepsis
Comparison
Ailanthone treatment vs control in septic mice and in vitro cardiomyocytes
Design
Preclinical in vitro and in vivo animal study
Key result
Inhibition of hexokinase 2 with ailanthone attenuated myocardial injury and improved cardiac function in a murine model of sepsis by targeting the lactate-H4K16la pathway.
Authors
Loading...
Should not yet change septic cardiomyopathy practice; leaves open histone lactylation as hypothesis-generating therapeutic target.
Ailanthone attenuates myocardial injury and improves cardiac function in a murine model of septic cardiomyopathy by inhibiting HK2 and reducing MOF-mediated H4K16 lactylation-driven inflammation.
Zhou et al. (2026) studied Septic cardiomyopathy. Ailanthone (AIL) was evaluated on Myocardial injury and cardiac function. Inhibition of hexokinase 2 with ailanthone attenuated myocardial injury and improved cardiac function in a murine model of sepsis by targeting the lactate-H4K16la pathway.